Skip to main content

Compare Stocks

Date Range: 

 Odonate TherapeuticsLiminal BioSciencesHepion PharmaceuticalsOrgenesisGlycoMimetics
SymbolNASDAQ:ODTNASDAQ:LMNLNASDAQ:HEPANASDAQ:ORGSNASDAQ:GLYC
Price Information
Current Price$2.88$4.28$1.59$5.06$2.41
52 Week RangeHoldHoldBuyN/ABuy
MarketRank™
Overall Score1.81.11.10.31.7
Analysis Score3.03.10.00.03.5
Community Score2.11.82.80.02.7
Dividend Score0.00.00.00.00.0
Ownership Score2.50.01.70.01.7
Earnings & Valuation Score1.30.61.31.30.6
Analyst Ratings
Consensus RecommendationHoldHoldBuyN/ABuy
Consensus Price Target$19.33$18.00$80.00N/A$13.00
% Upside from Price Target571.30% upside320.56% upside4,931.45% upsideN/A439.42% upside
Trade Information
Market Cap$111.18 million$128.16 million$121.20 million$123.87 million$124.21 million
Beta0.661.871.471.162.46
Average Volume3,128,738705,7504,798,395374,622860,397
Sales & Book Value
Annual RevenueN/A$3.70 millionN/A$33.26 millionN/A
Price / SalesN/A34.64N/A3.72N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$5.06 per share$3.06 per share$4.19 per share$0.38 per share$3.56 per share
Price / BookN/A1.40N/A13.32N/A
Profitability
Net Income$-111,820,000.00$-155,020,000.00$-6,720,000.00$-28,220,000.00$-57,890,000.00
EPS($4.05)($10.94)($5.95)N/A($1.34)
Trailing P/E RatioN/AN/AN/A1.09N/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-2,758.32%N/A600.61%N/A
Return on Equity (ROE)-85.75%-196.39%-116.73%6.25%-34.22%
Return on Assets (ROA)-71.45%-88.62%-78.47%3.77%-31.43%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A2.42%0.02%0.12%N/A
Current Ratio6.68%2.17%3.63%7.69%14.83%
Quick Ratio6.68%1.75%3.63%7.68%14.83%
Ownership Information
Institutional Ownership Percentage96.00%13.45%2.97%23.84%82.15%
Insider Ownership Percentage48.90%N/A0.10%7.22%26.80%
Miscellaneous
Employees1372511311154
Shares Outstanding38.60 million29.94 million76.23 million24.48 million51.54 million
Next Earnings Date7/29/2021 (Estimated)5/19/2021 (Estimated)7/5/2021 (Estimated)8/6/2021 (Estimated)7/30/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableNot OptionableOptionable
SourceHeadline
Anemia Drugs Market – 2021 Predictive Analytics |Amgen Inc, GlaxoSmithKline plc, Bluebird bio, Biocon, GlycoMimetics Inc – The Manomet Current - The Manomet CurrentAnemia Drugs Market – 2021 Predictive Analytics |Amgen Inc, GlaxoSmithKline plc, Bluebird bio, Biocon, GlycoMimetics Inc – The Manomet Current - The Manomet Current
manometcurrent.com - May 15 at 11:12 AM
Is GlycoMimetics Inc (GLYC) a Leader in the Biotechnology Industry? - InvestorsObserverIs GlycoMimetics Inc (GLYC) a Leader in the Biotechnology Industry? - InvestorsObserver
investorsobserver.com - May 14 at 12:29 PM
Iron Deficiency Anemia Drug Market to Witness Rapid Growth by 2027 | Acceleron Pharma, GlycoMimetics, Bluebird bio – Test & Measurement - Test & MeasurementIron Deficiency Anemia Drug Market to Witness Rapid Growth by 2027 | Acceleron Pharma, GlycoMimetics, Bluebird bio – Test & Measurement - Test & Measurement
testmeasurement.com.au - May 14 at 1:00 AM
2 “Strong Buy” Penny Stocks That Could See Outsized Gains - Smarter Analyst2 “Strong Buy” Penny Stocks That Could See Outsized Gains - Smarter Analyst
smarteranalyst.com - May 14 at 1:00 AM
Is GlycoMimetics Inc (GLYC) a Stock to Watch After Gaining 9.57% This Week? - InvestorsObserverIs GlycoMimetics Inc (GLYC) a Stock to Watch After Gaining 9.57% This Week? - InvestorsObserver
investorsobserver.com - May 14 at 1:00 AM
2 “Strong Buy” Penny Stocks That Could See Outsized Gains - Yahoo Finance2 “Strong Buy” Penny Stocks That Could See Outsized Gains - Yahoo Finance
finance.yahoo.com - May 13 at 12:31 PM
-$0.31 Earnings Per Share Expected for GlycoMimetics, Inc. (NASDAQ:GLYC) This Quarter-$0.31 Earnings Per Share Expected for GlycoMimetics, Inc. (NASDAQ:GLYC) This Quarter
americanbankingnews.com - May 12 at 5:36 PM
Galectin 3 Market 2021: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top Players: Angion Biomedica Corp, GlycoMimetics Inc, Bristol-Myers Squibb Company, Galectin Therapeutics Inc, MandalMed Inc, etc. – Brockville Observer - Brockville ObserverGalectin 3 Market 2021: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top Players: Angion Biomedica Corp, GlycoMimetics Inc, Bristol-Myers Squibb Company, Galectin Therapeutics Inc, MandalMed Inc, etc. – Brockville Observer - Brockville Observer
thebrockvilleobserver.ca - May 12 at 10:59 AM
GlycoMimetics, Inc.s (NASDAQ:GLYC) CEO Might Not Expect Shareholders To Be So Generous This Year - Yahoo FinanceGlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Might Not Expect Shareholders To Be So Generous This Year - Yahoo Finance
finance.yahoo.com - May 12 at 10:59 AM
GlycoMimetics, Inc.s (NASDAQ:GLYC) CEO Might Not Expect Shareholders To Be So Generous This YearGlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Might Not Expect Shareholders To Be So Generous This Year
finance.yahoo.com - May 12 at 10:59 AM
Hemoglobinopathy Treatment Drug Market 2021 Data Analysis and brief review – Bristol-Myers Squibb Company, GlycoMimetics, Pfizer, Anthera Pharmaceuticals – Clark County Blog - Clark County BlogHemoglobinopathy Treatment Drug Market 2021 Data Analysis and brief review – Bristol-Myers Squibb Company, GlycoMimetics, Pfizer, Anthera Pharmaceuticals – Clark County Blog - Clark County Blog
clarkcountyblog.com - May 7 at 6:09 PM
GlycoMimetics(NASDAQ:GLYC) Share Price Is Down 87% Over The Past Three Years. - Yahoo FinanceGlycoMimetics'(NASDAQ:GLYC) Share Price Is Down 87% Over The Past Three Years. - Yahoo Finance
finance.yahoo.com - May 5 at 4:04 PM
GlycoMimetics(NASDAQ:GLYC) Share Price Is Down 87% Over The Past Three Years.GlycoMimetics'(NASDAQ:GLYC) Share Price Is Down 87% Over The Past Three Years.
finance.yahoo.com - May 5 at 4:04 PM
Global CXCR4 Antagonists Market by Type (BL-8040, GMI-1359, Plerixafor (AMD3100), Balixafortide (POL6326), USL311, Others), By Application (Cancer, HIV, Chronic Inflammatory Diseases) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028 - Good News GumGlobal CXCR4 Antagonists Market by Type (BL-8040, GMI-1359, Plerixafor (AMD3100), Balixafortide (POL6326), USL311, Others), By Application (Cancer, HIV, Chronic Inflammatory Diseases) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028 - Good News Gum
goodnewsgum.com - May 4 at 5:21 PM
GlycoMimetics (NASDAQ:GLYC) Issues Quarterly  Earnings ResultsGlycoMimetics (NASDAQ:GLYC) Issues Quarterly Earnings Results
americanbankingnews.com - May 4 at 8:35 AM
GlycoMimetics Inc (GLYC) Q1 2021 Earnings Call Transcript - The Motley FoolGlycoMimetics Inc (GLYC) Q1 2021 Earnings Call Transcript - The Motley Fool
fool.com - May 3 at 9:15 PM
GlycoMimetics (NASDAQ:GLYC) Price Target Increased to $9.00 by Analysts at Stifel NicolausGlycoMimetics (NASDAQ:GLYC) Price Target Increased to $9.00 by Analysts at Stifel Nicolaus
americanbankingnews.com - May 3 at 5:32 PM
Analysts Offer Insights on Healthcare Companies: GlycoMimetics (GLYC), Eli Lilly & Co (LLY) and Sanofi (OtherSNYNF) - Smarter AnalystAnalysts Offer Insights on Healthcare Companies: GlycoMimetics (GLYC), Eli Lilly & Co (LLY) and Sanofi (OtherSNYNF) - Smarter Analyst
smarteranalyst.com - May 3 at 4:14 PM
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2021 - Business WireGlycoMimetics Reports Highlights and Financial Results for First Quarter 2021 - Business Wire
businesswire.com - May 3 at 10:18 AM
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2021GlycoMimetics Reports Highlights and Financial Results for First Quarter 2021
finance.yahoo.com - May 3 at 10:17 AM
Glycobiology (Diagnostics and Therapeutics) Market 2027 COVID-19 Impact Analysis : Biomarin Pharmaceutical Inc., Glycosensors And Diagnostics Llc, Glycomimetics, Glycan Biosciences Llc, Glycotest Inc. - Clark County BlogGlycobiology (Diagnostics and Therapeutics) Market 2027 COVID-19 Impact Analysis : Biomarin Pharmaceutical Inc., Glycosensors And Diagnostics Llc, Glycomimetics, Glycan Biosciences Llc, Glycotest Inc. - Clark County Blog
clarkcountyblog.com - May 1 at 9:36 AM
GlycoMimetics to Report First Quarter Financial Results on May 3, 2021 - Joplin GlobeGlycoMimetics to Report First Quarter Financial Results on May 3, 2021 - Joplin Globe
joplinglobe.com - April 28 at 12:50 PM
GlycoMimetics to Report First Quarter Financial Results on May 3, 2021 - ManchestertimesGlycoMimetics to Report First Quarter Financial Results on May 3, 2021 - Manchestertimes
manchestertimes.com - April 27 at 1:00 PM
GlycoMimetics (GLYC) Set to Announce Quarterly Earnings on MondayGlycoMimetics (GLYC) Set to Announce Quarterly Earnings on Monday
americanbankingnews.com - April 27 at 10:40 AM
GlycoMimetics to Report First Quarter Financial Results on May 3, 2021 - Yahoo FinanceGlycoMimetics to Report First Quarter Financial Results on May 3, 2021 - Yahoo Finance
finance.yahoo.com - April 26 at 8:01 PM
DateCompanyBrokerageAction
3/22/2021Odonate TherapeuticsLifesci CapitalDowngrade
3/22/2021Odonate TherapeuticsThe Goldman Sachs GroupLower Price Target
3/22/2021Odonate TherapeuticsJefferies Financial GroupDowngrade
3/22/2021Odonate TherapeuticsCowenDowngrade
9/9/2020Odonate TherapeuticsCi CapitalReiterated Rating
3/26/2021Liminal BioSciencesLeede Jones GabReiterated Rating
2/25/2021Liminal BioSciencesHC WainwrightInitiated Coverage
1/29/2021Liminal BioSciencesBloom BurtonDowngrade
12/21/2020Liminal BioSciencesPiper SandlerInitiated Coverage
8/11/2020Liminal BioSciencesEchelon Wealth PartnersReiterated Rating
12/1/2020Hepion PharmaceuticalsRoth CapitalBoost Price Target
9/26/2019OrgenesisBenchmarkInitiated Coverage
12/20/2018OrgenesisDawson JamesReiterated Rating
5/3/2021GlycoMimeticsStifel NicolausBoost Price Target
11/7/2019GlycoMimeticsPiper Jaffray CompaniesReiterated Rating
8/5/2019GlycoMimeticsSunTrust BanksDowngrade
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.